Materials for OINDP
Baseline Requirements Document
The IPAC-RS OINDP Materials Working Group has worked with suppliers to develop baseline requirements for materials used to manufacture components for OINDP. The impetus for this document was based on requests for a uniform set of requirements arising from several discussions between pharmaceutical manufacturers, regulators and multiple suppliers in meetings sponsored by IPAC-RS. As there is no single guidance for these types of materials, these requirements were compiled from a variety of international regulatory and compendial guidelines and standards. A copy of the Baseline Requirements for Materials used in Orally Inhaled and Nasal Drug Products (OINDP) is available here: Baseline Requirements.
13-14 September 2009 Materials Forum
The IPAC-RS OINDP Materials Working Group hosted a 1.5 day Materials Forum held in Philadelphia, PA on Sunday-Monday, 13-14 September 2009. The Forum brought together pharma, suppliers, and regulators to address challenges and develop solutions in materials supply and testing for OINDP. The Forum advanced discussion on key issues noted during the Barcelona Materials Forum that was held on 12 May. Click here for the final program: Final Program.
Click on the following links to access the slides from the September 2009 Forum.
12 May 2009 Materials Forum
The IPAC-RS OINDP Materials Working Group hosted a Materials Forum in Barcelona, Spain on Tuesday, 12 May 2009. The Forum brought together pharma, suppliers, and regulators to address challenges and develop solutions in materials supply and testing for OINDP.
The Final Program is available here: Final Program.
Click on the following links to access the slides from the May 2009 Forum.
Material Variability: How Much?
Kumudini Nicholas, Health Canada
Cheryl Stults, Novartis
Steve Lovatt, Bespak
Guido Draijer
Focus Testing: Is it Possible?
Prasad Peri, FDA
Mike Hodgson, Pfizer
Current Initiatives to Promote Product Quality and Safety (Materials Focus)
IPAC-RS - Barbara Falco, Abbott
Polymer Forum - Taina Tjäder, Bayer Schering Pharma Oy
ELSIE - Andrew Feilden, AstraZeneca
|